GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Cash Conversion Cycle

Societal CDMO (Societal CDMO) Cash Conversion Cycle : 95.14 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Societal CDMO's Days Sales Outstanding for the three months ended in Dec. 2023 was 51.6.
Societal CDMO's Days Inventory for the three months ended in Dec. 2023 was 51.37.
Societal CDMO's Days Payable for the three months ended in Dec. 2023 was 7.83.
Therefore, Societal CDMO's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 95.14.


Societal CDMO Cash Conversion Cycle Historical Data

The historical data trend for Societal CDMO's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Cash Conversion Cycle Chart

Societal CDMO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.11 144.82 105.41 99.00 105.16

Societal CDMO Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.87 108.72 112.06 102.41 95.14

Competitive Comparison of Societal CDMO's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Cash Conversion Cycle falls into.



Societal CDMO Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Societal CDMO's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=62.73+49.06-6.63
=105.16

Societal CDMO's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=51.6+51.37-7.83
=95.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Societal CDMO  (NAS:SCTL) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Societal CDMO Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO (Societal CDMO) Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.
Executives
Bryan M. Reasons director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant director C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr director, officer: Chief Executive Officer
James Charles Miller director 490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens director, 10 percent owner C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc director, 10 percent owner 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks director C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz director 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p. 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355